Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

The objective of this study is to assess the safety, efficacy, and pharmacokinetics of SA53-OS in adult participants with refractory solid tumors. The study is comprised of 2 parts: Part 1 called dose escalation, and Part 2a called dose expansion. This study starts with Part 1 where participants who are diagnosed with advanced or metastatic solid tumor cancers receive different doses of SA53-OS (starting with the lowest dose) to find the maximum tolerated dose (MTD) of SA53-OS. Once the MTD of SA53-OS is known, the study continues to Part 2a where participants who are diagnosed with dediffere

Trial Details

NCT ID
NCT06578624
Phase
PHASE1 / PHASE2
Sponsor
Lamassu Bio Inc
Status
RECRUITING
Cancer Type
Liposarcoma Sarcoma
Interventions
  • SA53-OS (phase 1)
  • SA53-OS (phase 2)
Locations (sample)
  • Canton, Ohio, United States|40.79895,-81.37845
  • Cleveland, Ohio, United States|41.4995,-81.69541
  • Cleveland, Ohio, United States|41.4995,-81.69541

Key Eligibility Criteria

  • Tumor characteristics of participants in Phase 1
  • Histologically and/or cytologically confirmed diagnosis of advanced or metastatic solid tumor and/or non-Hodgkin lymphoma excluding primary central…
  • Tumor p53 wild-type.
  • Tumor characteristics of participants in Phase 2a

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liposarcoma Sarcoma Trials on Trialify →